Compare SIMO & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIMO | SYRE |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | Hong Kong | United States |
| Employees | N/A | 112 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.6B |
| IPO Year | 2005 | 2015 |
| Metric | SIMO | SYRE |
|---|---|---|
| Price | $279.94 | $86.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $118.13 | $85.08 |
| AVG Volume (30 Days) | 708.6K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.27 | N/A |
| Revenue Next Year | $12.78 | N/A |
| P/E Ratio | $36.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $79.76 | $15.49 |
| 52 Week High | $355.00 | $110.18 |
| Indicator | SIMO | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 56.32 | 37.10 |
| Support Level | $230.06 | $82.83 |
| Resistance Level | $314.34 | $93.65 |
| Average True Range (ATR) | 15.86 | 3.70 |
| MACD | 3.07 | -0.07 |
| Stochastic Oscillator | 81.50 | 27.33 |
Silicon Motion Technology Corp is engaged in developing NAND flash controllers for SSDs and other solid-state storage devices. Its only operating segment is to develop NAND flash controllers and SSD solutions. The company derives revenue from product categories such as Mobile Storage, Mobile Communications, and others. Silicon's geographical segments are Taiwan, the United States, Korea, China, Singapore, Malaysia, and others. The company's products are used in Personal Computing, Smartphone/Tablet/CE, Flash Card/USB Flash Drive, Industrial and Embedded, Automotive, and Enterprise and Data centers.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.